Paul Schimmel, Director at aTYR PHARMA INC (LIFE), bought 150,000 shares at $1.00 ($150K) on 2018-05-18, disclosed to the SEC on 2018-05-21.
Open-market purchase of $150k LIFE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| ATYR | BUY | 2024-07-24 | $256K | — | Filing → |
| LIFE | BUY | 2023-05-11 | $450K | — | Filing → |
| LIFE | BUY | 2021-09-22 | $2.0M | — | Filing → |